Psoriasis flare-up; Joint range of motion decreased / could not move fingers; This spontaneous case was reported by a consumer and describes the occurrence of PSORIASIS (Psoriasis flare-up) in an adult male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination. The occurrence of additional non-serious events is detailed below.    Co-suspect product included non-company product ADALIMUMAB (HUMIRA) for Psoriasis.    Concurrent medical conditions included Psoriasis.   On 20-May-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 20-Jun-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) dosage was changed to 1 dosage form. On an unknown date, the patient started ADALIMUMAB (HUMIRA) (Subcutaneous) at an unspecified dose. On an unknown date, the patient experienced PSORIASIS (Psoriasis flare-up) (seriousness criterion medically significant) and JOINT RANGE OF MOTION DECREASED (Joint range of motion decreased / could not move fingers). At the time of the report, PSORIASIS (Psoriasis flare-up) and JOINT RANGE OF MOTION DECREASED (Joint range of motion decreased / could not move fingers) outcome was unknown.            No concomitant and treatment medications were reported. The patient had four back surgeries and two neck surgeries. It was unknown if patient was enrolled in COVID-19 vaccine trail. Blistered and plaque  all around the body, toes nails fell off (nail loss) and fingers swollen were the reported symptoms related to Psoriasis flare up.   This case was identified as part of a retrospective clean-up activity where certain emails received in the Moderna mailbox were missed to be booked-in  Company comment: This spontaneous case concerns an adult male patient, with relevant medical history of psoriasis on Adalimumab, who experienced the unexpected serious (medically significant) event of Psoriasis (reported as Psoriasis flare-up) on an unknown date in the context of receiving a dose of mRNA-1273 vaccine. Onset latency could not be determined as onset date of event was not provided. It was reported that after vaccination, patient had psoriasis flare up since then, presented as blister and plaque all around the body, swollen fingers, and toenails fall off. Clinical course and treatment details were not reported. The outcome of event was reported as unknown. Patient received 2-dose primary series of mRNA-1273 vaccine at an interval of 31 days, which is within the recommended dosing schedule. On an unknown date, the patient received Adalimumab for psoriasis, which could be considered as a confounder as disease itself is known to flares. The benefit-risk relationship of mRNA-1273 is not affected by this report.   Most recent FOLLOW-UP information incorporated above includes: On 18-Apr-2022: Follow-up received include Event (PSORIASIS) added.; Sender's Comments: This spontaneous case concerns an adult male patient, with relevant medical history of psoriasis on Adalimumab, who experienced the unexpected serious (medically significant) event of Psoriasis (reported as Psoriasis flare-up) on an unknown date in the context of receiving a dose of mRNA-1273 vaccine. Onset latency could not be determined as onset date of event was not provided. It was reported that after vaccination, patient had psoriasis flare up since then, presented as blister and plaque all around the body, swollen fingers, and toenails fall off. Clinical course and treatment details were not reported. The outcome of event was reported as unknown. Patient received 2-dose primary series of mRNA-1273 vaccine at an interval of 31 days, which is within the recommended dosing schedule. On an unknown date, the patient received Adalimumab for psoriasis, which could be considered as a confounder as disease itself is known to flares. The benefit-risk relationship of mRNA-1273 is not affected by this report.